Efficiency of Protease-Activatable Virus Nanonodes Tuned Through Incorporation of Wild-Type Capsid Subunits

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Cellular and Molecular Bioengineering

• Publication date

  2014-07-15

• Fields of study

  Biology, Materials Science, Engineering

• Identifiers
  DOI 10.1007/S12195-014-0334-Y
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Tunable Protease-Activatable Virus Nanonodes

  2014cited by this paper
• Real-time in vivo molecular detection of primary tumors and metastases with ratiometric activatable cell-penetrating peptides.

  2013cited by this paper
• SCHEMA computational design of virus capsid chimeras: calibrating how genome packaging, protection, and transduction correlate with calculated structural disruption.

  2013cited by this paper
• Site-specific modification of adeno-associated viruses via a genetically engineered aldehyde tag.

  2013cited by this paper
• Directed evolution of adeno-associated virus for enhanced gene delivery and gene targeting in human pluripotent stem cells.

  2012cited by this paper
• Random Insertion of mCherry Into VP3 Domain of Adeno-associated Virus Yields Fluorescent Capsids With no Loss of Infectivity

  2012cited by this paper
• A Perspective on Cancer Cell Metastasis

  2011cited by this paper
• An evolved adeno-associated viral variant enhances gene delivery and gene targeting in neural stem cells.

  2011cited by this paper
• Glycated AAV vectors: chemical redirection of viral tissue tropism.

  2011cited by this paper
• Directed evolution of adeno-associated virus for glioma cell transduction

  2010cited by this paper
• A myocardium tropic adeno-associated virus (AAV) evolved by DNA shuffling and in vivo selection

  2009cited by this paper
• Adeno-associated virus-2 and its primary cellular receptor--Cryo-EM structure of a heparin complex.

  2009cited by this paper
• Matrix metalloproteinases and their multiple roles in neurodegenerative diseases.

  2009cited by this paper
• Clinical gene therapy using recombinant adeno-associated virus vectors

  2008cited by this paper
• Coating of adeno‐associated virus with reactive polymers can ablate virus tropism, enable retargeting and provide resistance to neutralising antisera

  2008cited by this paper
• Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial.

  2007cited by this paper
• Oncolytic efficacy and enhanced safety of measles virus activated by tumor-secreted matrix metalloproteinases.

  2006cited by this paper
• Phase I Trial of Intramuscular Injection of a Recombinant Adeno-Associated Virus Alpha 1-Antitrypsin (rAAV2-CB-hAAT) Gene Vector to AAT-Deficient Adults

  2004cited by this paper
• Cross-Dressing the Virion: the Transcapsidation of Adeno-Associated Virus Serotypes Functionally Defines Subgroups

  2004cited by this paper
• Markers of Inflammation and Rapid Coronary Artery Disease Progression in Patients With Stable Angina Pectoris

  2004cited by this paper
• Role of proteases in the pathophysiology of cardiac disease

  2004cited by this paper
• Immune Responses to Recombinant Adeno-Associated Virus Vectors: Putting Preclinical Findings into Perspective

  2004cited by this paper
• Identification of Amino Acid Residues in the Capsid Proteins of Adeno-Associated Virus Type 2 That Contribute to Heparan Sulfate Proteoglycan Binding

  2003cited by this paper
• Generation and characterization of chimeric recombinant AAV vectors.

  2003cited by this paper
• Matrix metalloproteinases: a review of their structure and role in acute coronary syndrome.

  2003cited by this paper
• Matrix metalloproteinases in neuroinflammation

  2002cited by this paper
• New functions for the matrix metalloproteinases in cancer progression

  2002cited by this paper
• The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy

  2002cited by this paper
• Conjugate-Based Targeting of Recombinant Adeno-Associated Virus Type 2 Vectors by Using Avidin-Linked Ligands

  2002cited by this paper
• Cell-Type-Specific Characteristics Modulate the Transduction Efficiency of Adeno-Associated Virus Type 2 and Restrain Infection of Endothelial Cells

  2002cited by this paper
• Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells.

  2001cited by this paper
• A Gene Delivery System Activatable by Disease-Associated Matrix Metalloproteinases

  1997cited by this paper
• Tumor and stromal expression of matrix metalloproteinases and their role in tumor progression.

  1994cited by this paper
• Metalloproteinases in tumor progression: the contribution of MMP-9.

  1994cited by this paper

• Structural polymorphism in protein cages and virus-like particles.

  2023cites this paper
• Cytochrome C with peroxidase-like activity encapsulated inside the small DPS protein nanocage.

  2021cites this paper
• Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects

  2020cites this paper
• Constructing and evaluating caspase-activatable adeno-associated virus vector for gene delivery to injured heart.

  2020cites this paper
• Synthetically Engineered Adeno-Associated Virus for Efficient, Safe, and Versatile Gene Therapy Applications.

  2020cites this paper
• Protease-Activatable Adeno-Associated Virus Vector for Gene Delivery to Damaged Heart Tissue.

  2019cites this paper
• Physical, chemical, and synthetic virology: Reprogramming viruses as controllable nanodevices.

  2019cites this paper
• Longer Inactivating Sequence in Peptide Lock Improves Performance of Synthetic Protease-Activatable Adeno-Associated Virus.

  2019cites this paper
• Reducing off target viral delivery in ovarian cancer gene therapy using a protease-activated AAV2 vector platform.

  2019cites this paper
• Adeno-Associated Virus (AAV) Vectors: Rational Design Strategies for Capsid Engineering.

  2018cites this paper
• Stimulus‐responsive viral vectors for controlled delivery of therapeutics

  2017cites this paper
• Role of Tetra Amino Acid Motif Properties on the Function of Protease-Activatable Viral Vectors.

  2016cites this paper
• Light-Activated Nuclear Translocation of Adeno-Associated Virus Nanoparticles Using Phytochrome B for Enhanced, Tunable, and Spatially Programmable Gene Delivery.

  2016cites this paper
• Generation of Targeted Adeno-Associated Virus (AAV) Vectors for Human Gene Therapy.

  2015cites this paper
• The Fractal (BSf) Kinetics Equation and Its Approximations

  2014cites this paper
• Synthetic virology: engineering viruses for gene delivery.

  2014cites this paper